Form 4: Royalty Pharma EVP Christopher Hite Acquires 300,000 Class A Ordinary Shares Through Exchange
SEC Form 4 Filing
Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, acquired 300,000 Class A Ordinary Shares through an exchange of limited partnership interests.
Summary
- Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, reported a transaction on February 14, 2025.
- Hite acquired 300,000 Class A Ordinary Shares through an exchange of limited partnership interests in RPI US Partners 2019, LP.
- The exchange was made pursuant to the Exchange Agreement dated June 16, 2020.
- Hite also disposed of 70,000 Class A Ordinary Shares.
- Following the transaction, Hite directly owns 0 Class A Ordinary Shares and indirectly owns 600,000 Class A Ordinary Shares through SCH Investment Partners LLC.
- Hite also indirectly owns 86,641 LP interests in RPI US Partners 2019, LP through SCH Investment Partners LLC.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects a standard transaction involving the exchange of partnership interests for shares, with no explicit positive or negative implications.
Industry Context
This Form 4 filing indicates changes in beneficial ownership by a company insider, which is a common occurrence and is closely monitored by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The transaction may be of interest to shareholders as it reflects insider activity.
Key Dates
| Date | Description |
|---|---|
| June 16, 2020 | Date of the Exchange Agreement among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP. |
| February 14, 2025 | Date of the transaction where Christopher Hite acquired 300,000 Class A Ordinary Shares and disposed of 70,000 Class A Ordinary Shares. |
| February 18, 2025 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.